Tags

Type your tag names separated by a space and hit enter

Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Prescrire Int. 2001 Dec; 10(56):180-1.PI

Abstract

(1) The reference symptomatic treatment for mild to moderate Alzheimer's disease is a cholinesterase inhibitor such as donepezil, but efficacy is only moderate and only about 10% of those patients treated actually benefit. (2) Galantamine is the fourth cholinesterase inhibitor to be marketed in France for Alzheimer's disease. The clinical file contains data from five double-blind placebo-controlled trials lasting 3-6 months, but no data comparing galantamine with other drugs. (3) These trials show that about 5-13% of patients treated with galantamine may be improved. (4) Adverse effects are very frequent, and are similar to those of other cholinesterase inhibitors, i.e. nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, etc. (5) For patients who are eligible for drug therapy, the reference treatment is still donepezil, for want of anything better.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

11824442

Citation

"Galantamine: New Preparation. the Fourth Cholinesterase Inhibitor for Alzheimer's Disease." Prescrire International, vol. 10, no. 56, 2001, pp. 180-1.
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. Prescrire Int. 2001;10(56):180-1.
(2001). Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. Prescrire International, 10(56), 180-1.
Galantamine: New Preparation. the Fourth Cholinesterase Inhibitor for Alzheimer's Disease. Prescrire Int. 2001;10(56):180-1. PubMed PMID: 11824442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. PY - 2002/2/5/pubmed PY - 2002/4/9/medline PY - 2002/2/5/entrez SP - 180 EP - 1 JF - Prescrire international JO - Prescrire Int VL - 10 IS - 56 N2 - (1) The reference symptomatic treatment for mild to moderate Alzheimer's disease is a cholinesterase inhibitor such as donepezil, but efficacy is only moderate and only about 10% of those patients treated actually benefit. (2) Galantamine is the fourth cholinesterase inhibitor to be marketed in France for Alzheimer's disease. The clinical file contains data from five double-blind placebo-controlled trials lasting 3-6 months, but no data comparing galantamine with other drugs. (3) These trials show that about 5-13% of patients treated with galantamine may be improved. (4) Adverse effects are very frequent, and are similar to those of other cholinesterase inhibitors, i.e. nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, etc. (5) For patients who are eligible for drug therapy, the reference treatment is still donepezil, for want of anything better. SN - 1167-7422 UR - https://www.unboundmedicine.com/medline/citation/11824442/Galantamine:_new_preparation__The_fourth_cholinesterase_inhibitor_for_Alzheimer's_disease_ L2 - https://medlineplus.gov/alzheimersdisease.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.